# BPC-157 FAQ: Safety, Effects, and Legal Status Questions Answered > BPC-157 FAQ: direct, cited answers on safety, liver and kidney and heart effects, cancer concerns, oral use, legal status, and the 503A category, drawn from the published record. Short, direct, cited answers — drawn from the published BPC-157 record, with the honest caveats kept in plain view. ## Can BPC-157 be taken orally? BPC-157 is termed a stable gastric pentadecapeptide because it is reported stable in human gastric juice, which underlies research interest in oral and peroral dosing; formal human oral pharmacokinetics are not established [10]. Animal gastrointestinal studies used both intragastric and parenteral routes [4]. ## Does oral BPC-157 work? In rat gastric-ulcer work, intramuscular delivery outperformed intragastric, and pharmacokinetic data show modest intramuscular bioavailability with rapid breakdown [2][4]. Oral efficacy in humans has not been established in controlled trials. ## Do BPC-157 pills work? There are no controlled human trials demonstrating oral-capsule efficacy. The gastric-stability rationale is preclinical; the reported human data come from injectable pilot studies, not pills [8][13]. ## What does BPC-157 do in the body? In animal models, BPC-157 is described as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis via VEGFR2-Akt-eNOS signaling, alongside nitric-oxide-system and other pathway modulation [3][5]. These are findings in cells and animals. ## Is BPC-157 a growth hormone? No. BPC-157 is a 15-amino-acid peptide derived from a gastric-juice protein, not a growth hormone; in tendon-fibroblast studies it up-regulated the growth-hormone receptor rather than acting as the hormone itself [1]. ## Does BPC-157 work immediately? Animal studies measure healing over days to weeks, not minutes. There is no human evidence defining an onset timeline, and claims of immediate effect are not supported by the published research [9]. ## Does BPC-157 damage the liver? Animal work reports hepatoprotective rather than hepatotoxic effects, and a two-person intravenous safety pilot found no measurable hepatic-biomarker changes [7][8]. Human safety data remain extremely limited, so liver risk is genuinely uncharacterized. ## Is BPC-157 hard on the kidneys? The small intravenous human pilot reported no measurable renal-biomarker changes, and animal studies do not flag a nephrotoxic signal [8]. However, no large or long-term human safety data exist, so renal safety is not established. ## Can BPC-157 mess with your heart? The two-person intravenous safety pilot reported no measurable cardiac-biomarker changes [8]. Cardiac effects are otherwise studied only in rodent disease models, and the human cardiac safety profile is unknown. ## Is BPC-157 bad for the heart? No human evidence indicates cardiac harm within the tiny dataset, and the intravenous pilot showed no biomarker changes [8]. But the absence of large controlled trials means cardiac safety cannot be assured. ## Can BPC-157 cause liver damage? Published animal studies describe protection against several liver-injury models rather than damage, and the human intravenous pilot found no hepatic-biomarker changes [7][8]. Definitive human liver-safety data are still lacking. ## What happens when you stop taking BPC-157? No human studies characterize discontinuation effects. The peptide has a very short elimination half-life — under 30 minutes in animal pharmacokinetics — so it is cleared rapidly, but withdrawal-type outcomes are not established [2]. ## How long should I stay on BPC-157? No validated human dosing duration exists. Animal studies use fixed experimental schedules tied to each model's endpoint, and this site reports research figures only [1][9]. It does not provide human dosing or duration guidance — see the [how BPC-157 doses are expressed](/dosage) page for how the research figures are stated. ## What should you not mix with BPC-157? There are no human drug-interaction studies. Some rodent work explores BPC-157 counteracting NSAID-induced injury, but this is preclinical, and no validated interaction guidance for humans exists [9]. ## How does BPC-157 make you feel? There are no controlled human experiential data. Rodent central-nervous-system studies describe serotonergic and dopaminergic modulation via a proposed brain-gut axis, but subjective human effects are not established [5]. ## How long does it take for BPC-157 to kick in? There is no defined human onset window. Preclinical outcomes are measured over an experiment's duration, not by a subjective "kick-in" time [1][9]. ## Can BPC-157 help with weight loss? Weight-loss claims are not supported by the published BPC-157 evidence; a 2025 narrative review notes that common online claims like weight loss are not backed by data and should be treated skeptically [9]. ## Can you drink alcohol while taking BPC-157? No human interaction data exist. Rodent studies have explored BPC-157 in alcohol-related gastric-lesion and liver models, but that is preclinical and does not translate to human guidance [7][9]. ## Does BPC-157 build muscle? Muscle-building is not supported by the evidence. Rodent work shows recovery from muscle crush injury, not anabolic growth, and a 2025 review lists muscle-building among unsupported popular claims [9]. ## Does BPC-157 cause cancer? There is no human evidence that BPC-157 causes cancer. Because it is pro-angiogenic via VEGFR2, a theoretical concern is sometimes raised — angiogenesis supports tumor blood supply — but no clinical data address it, and long-term human safety is unknown [3][9]. ## Can BPC-157 heal arthritis? Animal studies report tendon, ligament, and bone-defect healing, and a small uncontrolled human knee-pain case series reported improvement, but no controlled trial supports treating arthritis [1][13]. These are research findings, not a treatment claim. ## How long does BPC-157 take to work? Animal healing studies span days to weeks depending on tissue and model [1][4]. No human timeline has been established in controlled research [9]. ## Is BPC-157 legal? BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 — substances that may present significant safety risks — effective September 29, 2023, so it is not within FDA's enforcement-discretion policy for 503A compounding [1][2]. It is also prohibited in sport by the World Anti-Doping Agency. This is general information, not legal advice; see the [BPC-157 legal status and 503A category](/legal-status) page. ## Can you get BPC-157 from a compounding pharmacy? A compounding pharmacy may use a bulk substance only if it is eligible under the 503A or 503B rules; while BPC-157 stands in Category 2, it is not eligible for routine 503A compounding [1][2]. Lawful compounded access runs through a licensed-prescriber evaluation and a valid, patient-specific prescription. General information only; no pharmacy or provider is named. ## What is the FDA 503A status of BPC-157? FDA placed BPC-157 in 503A Category 2 — bulk substances that may present significant safety risks — effective with the September 29, 2023 nominated-substances update, citing immunogenicity and peptide-impurity concerns [2]. It is therefore outside FDA's 503A enforcement-discretion policy [1]. It is separately scheduled for PCAC discussion on July 23-24, 2026, which is an evaluation step, not a decision [3]. --- An engraved register of the BPC-157 literature, read in gold on black — not a clinic, not a pharmacy, not a prescription, and nothing here is for sale.